Current Environment: Production

Natalie Collins | Medical Services

Programs & Services

Languages

  • English

Natalie Collins | Education

Medical School

University of Virginia School of Medicine

2009, Charlottesville, VA

Internship

Boston Combined Residency Program (BCRP)

2010, Boston, MA

Residency

Pediatrics

Boston Combined Residency Program (BCRP)

2011, Boston, MA

Fellowship

Pediatric Hematology-Oncology

Dana-Farber/Boston Children's Cancer and Blood Disorders

2015, Boston, MA

Natalie Collins | Certifications

  • American Board of Pediatrics (General)
  • American Board of Pediatrics (Hematology-Oncology)

Natalie Collins | Publications

  1. Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics. Clin Cancer Res. 2024 Oct 01; 30(19):4363-4376. View Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics. Abstract

  2. Author Correction: Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. Nat Commun. 2024 Aug 22; 15(1):7218. View Author Correction: Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. Abstract

  3. Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. Nat Commun. 2024 Jul 11; 15(1):5837. View Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. Abstract

  4. Off-label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center. Cancer Med. 2024 Apr; 13(8):e7154. View Off-label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center. Abstract

  5. Early detection of malignant and pre-malignant peripheral nerve tumors using cell-free DNA fragmentomics. medRxiv. 2024 Mar 11. View Early detection of malignant and pre-malignant peripheral nerve tumors using cell-free DNA fragmentomics. Abstract

  6. A spatial cell atlas of neuroblastoma reveals developmental, epigenetic and spatial axis of tumor heterogeneity. bioRxiv. 2024 Jan 16. View A spatial cell atlas of neuroblastoma reveals developmental, epigenetic and spatial axis of tumor heterogeneity. Abstract

  7. Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency. Clin Cancer Res. 2023 12 01; 29(23):4770-4783. View Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency. Abstract

  8. Learning About Mismatch Repair From a Rare Cancer Syndrome: A LOGICal Step Forward. J Clin Oncol. 2023 02 01; 41(4):727-731. View Learning About Mismatch Repair From a Rare Cancer Syndrome: A LOGICal Step Forward. Abstract

  9. Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer. JCO Precis Oncol. 2022 11; 6:e2200390. View Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer. Abstract

  10. Derivation and validation of a risk classification tree for patients with synovial sarcoma. Cancer Med. 2023 01; 12(1):170-178. View Derivation and validation of a risk classification tree for patients with synovial sarcoma. Abstract

  11. PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment. J Immunother Cancer. 2022 03; 10(3). View PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment. Abstract

  12. Molecular Characterization of Inflammatory Tumors Facilitates Initiation of Effective Therapy. Pediatrics. 2021 12 01; 148(6). View Molecular Characterization of Inflammatory Tumors Facilitates Initiation of Effective Therapy. Abstract

  13. Author Correction: A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nat Med. 2020 Aug; 26(8):1307. View Author Correction: A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Abstract

  14. Role of Surgery in Rhabdomyosarcoma of the Head and Neck in Children. Laryngoscope. 2021 03; 131(3):E984-E992. View Role of Surgery in Rhabdomyosarcoma of the Head and Neck in Children. Abstract

  15. The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. Pediatr Blood Cancer. 2020 10; 67(10):e28559. View The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. Abstract

  16. A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nat Med. 2020 05; 26(5):792-802. View A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Abstract

  17. Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers. Clin Cancer Res. 2020 06 15; 26(12):2882-2890. View Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers. Abstract

  18. Pediatric post-transplant hepatic kaposi sarcoma due to donor-derived human herpesvirus 8. Pediatr Transplant. 2019 05; 23(3):e13384. View Pediatric post-transplant hepatic kaposi sarcoma due to donor-derived human herpesvirus 8. Abstract

  19. Binding of FANCI-FANCD2 Complex to RNA and R-Loops Stimulates Robust FANCD2 Monoubiquitination. Cell Rep. 2019 01 15; 26(3):564-572.e5. View Binding of FANCI-FANCD2 Complex to RNA and R-Loops Stimulates Robust FANCD2 Monoubiquitination. Abstract

  20. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. Nature. 2019 01; 565(7737):43-48. View Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. Abstract

  21. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 2017 07 27; 547(7664):413-418. View In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Abstract

  22. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017 04 03; 214(4):895-904. View PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. Abstract

  23. Use of a fever fast track tool to reduce time to antibiotic dose in febrile pediatric oncology patients. J Clin Oncol. 2014 Oct 20; 32(30_suppl):222. View Use of a fever fast track tool to reduce time to antibiotic dose in febrile pediatric oncology patients. Abstract

  24. ATR-dependent phosphorylation of FANCA on serine 1449 after DNA damage is important for FA pathway function. Blood. 2009 Mar 05; 113(10):2181-90. View ATR-dependent phosphorylation of FANCA on serine 1449 after DNA damage is important for FA pathway function. Abstract

BESbswy